Iscalimab - Novartis
Alternative Names: CFZ-533; NVP-CFZ533; OM11-62-MFLatest Information Update: 22 Jul 2024
At a glance
- Originator Novartis; XOMA
- Developer Novartis
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Monoclonal antibodies; Urologics
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Graves' disease; Hidradenitis suppurativa; Liver transplant rejection; Lupus nephritis; Myasthenia gravis; Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
- Phase I/II Renal transplant rejection
- No development reported Rheumatoid arthritis
Most Recent Events
- 12 Jun 2024 Efficacy and adverse events data from a phase IIb TWINSS trial in Sjogren's syndrome presented at the25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 04 Jun 2024 Novartis Pharmaceuticals completes a phase-II clinical trials in Type 1 diabetes mellitus (In children, In adults, In adolescents) in Belgium, Italy, Slovenia, Spain, United Kingdom (IV) (SC) (NCT04129528) (EudraCT2018-004553-25)
- 10 Nov 2023 Efficacy and adverse events data from a phase IIb TWINSS trial in Sjogren's syndrome presented at the ACR Convergence 2023